Qaadashada cayaaraha iyo u adeegsiga ujeedooyinka iyo shaqada dhabta ah ee nolosha, waxa loo yaqaan "gamification," ayaa horay u soconaya xawaaraha warshadaha ka dhasha aduunkeena oo ah digital-mobile. Horumarintu waxay ku samaysay qaybo badan oo kala duwan oo ay ka mid yihiin ciyaaraha is-nadiifinta, cayaaraha si loogu dhiirigeliyo isbeddellada hab-nololeed ee wanaagsan, iyo xitaa cayaaraha si loo kordhiyo dhiirrigelinta ujeeddooyinka shaqada.
Genentech, oo ah shirkad hormoon ah oo biopoferka ah, ayaa hadda ka dhigaysa sayniska ka dambeeya daaweynta kansarka - mana ahan kali. Laakiin sidee ayay udubdhexaadintu khuseysaa bukaanka kansarka? Waa hagaag, bukaanka qaba kansarka, isku dayaya inuu qorsheeyo mustaqbalka ayaa noqon kara mid adag. Jirdoonka sayniska, shuruudaha farsamo, gaabinta, iyo ereyada yaryar ma caawiyaan arrimaha. Waqtiga badbaadada, tusaale ahaan, waxaa loo qiyaasi karaa siyaabo kala duwan, iyo sidoo kale jawaabta bukaanka kansarka ee daaweynta. Taasi waa meesha Hawlgalka: MRD ku haboon tahay.
Hawlgalka: MRD
Genentech waxay abuurtay ciyaaro cusub oo 60-daqiiqo ah, Mission: MRD, si dadka loo baro cudurka halista ah ee loo yaqaan 'residual residual disease' (MRD) - waa hab lagu cabirayo jawaabta qofka ee jawaab celinta daaweynta kansarka ama daweynta.
Noocyo badan oo ka mid ah kansarka dhiigga - oo ay ka mid tahay leukemocytia leukemia (CLL), lafaha ugu badan ee dadka waawayn - ayaa ah noocyo u baahan in la xakameeyo daawooyinka ka hortagga kansarka waqti ka dambeeya, taasoo macnaheedu yahay inaysan waligaa ka takhalusi karin dhammaan unugyada kansarka ee ugu dambeeya.
Tani waxay keenaysaa soo noqoshada, markaa dhakhtarradu waxay isku dayaan inay aad u taxaddaraan marka ay timaado ereyga "daawo."
Hawlgalka: MRD, qof ayaa isticmaala dhiigga, isaga oo baabi'iya unugyada kansarka badan sababta oo ah waxay ku gaari karaan himilada lagu gaaro MRD-xasaasiyad. Waxaa muhiim ah in la ogaado in cayaartu ay tahay tan ugu muhiimsan madadaalada oo aan loogu talagelin inay ahaato mid caafimaad ama mid cilmi ahaanba sax ah, laakiin halkii ay kor u qaadi lahayd wacyiga MRD.
MRD-Dareen-xumo
Marka qof qaba CLL uu gaaro MRD-negativity, macnaheedu waa in unugyada kansarka laga heli karo shaybaarka dhiigga ama lafaha lafaha iyadoo la isticmaalayo tijaabooyin gaar ah. Hadda, kansarka sida CLL, weli waa suurtagal in cudurka uu soo laabto, xitaa ka dib markii bukaanku gaaray MRD-negativity; Si kastaba ha ahaatee, gaaritaanka MRD-negativity waxay u muuqataa inay tahay arrin fiican, waana sababta:
- Waxaa jira dhowr siyaabood oo lagu cabbiro culeyska cudurka kansarka. Xaaladda MRD-negative ee CLL waxaa suuragal ah in la helo tiknoolajiyad cusub oo cusub.
- Marka qof qaba CLL uu gaaro MRD-negativity, micnaheedu waa kansar lama ogaan karo shaybaarka dhiiga ama lafaha lafaha iyadoo la adeegsanayo tijaabooyin gaar ah oo isticmaala hababka xasaasiga ah ee loo isticmaalo hababka hore ee tirinta unugyada 100-ka yar ee mikroskoobka.
- MRD-negativity waxaa laga yaabaa in lala xiriiriyo natiijooyinka ka sii wanaagsan. Shaqooyin dheeraad ah ayaa loo baahan yahay in la sameeyo laakiin calaamadaha sii kordhaya ee caddaynta waxay muujinayaan in MRD-negativity ka dib daaweynaha qaarkood ay saadaalin karaan muddada dheer iyo muddada dheer ee mudada dheer ee kansarka dhiigga.
Ciyaaraha Kansarka mustaqbalka
Ciyaaro kale ayaa la qorsheeyay oo sawirro iyo sharaxyo kala duwan ayaa laga heli karaa bogga Genentech si ay kaaga caawiso inaad fahamto wareegga difaaca kansarka - habka u horseeda horumarinta difaaca jirka ee ka hortagga unugyada kansarka.
Ilaha:
Smolej L, Šimkovič M. Habka haqab-beelka ah ee loo maareeyo xaddiga lymphocytic leukemia. Archives of Sayniska Caafimaadka: AMS. 2016; 12 (2): 448-456.
Hallek M, Cheson BD, Catovsky D, et al. Tilmaamaha loogu talagalay ogaanshaha iyo daaweynta xajiinta lymfocytia ee joogtada ah: warbixinta ka socota Workshop ee Looxa Cudurka Lymphocytic Leukemia oo cusbooneysiinta cusbooneysiinta habka loo yaqaan 'National Cancer Institute-Working Group 1996'. Dhiiga . 2008; 111: 5446-56.
Hallek M, Fischer K, Fingerle-Rowson G, et al. Isku darista rituximab ee fludarabine iyo cyclophosphamide ee bukaanka qaba lymphocytic leukemia joogto ah: shay lagu kala soocay, furan, marxaladda 3aad. Lancet. 2010; 376: 1164-74.
Bottcher S, Ritgen M, Fischer K, iyo al. Qiyaasta ugu yar ee sii-haraaga cudurku waa mid madax-bannaan oo madax-bannaan oo aan loo baahnayn iyo guud ahaan guud ee noolaanshaha lymphocytic leukemia: falanqeyn kala duwan oo ka socda tijaabada GCLLSG CLL8. J Clin Oncol . 2012; 30: 980-8.